Does a negative β‑D‑glucan test exclude infection with dimorphic fungi?

Does a Negative β-D-Glucan Exclude Dimorphic Fungi?

No, a negative β-D-glucan (BDG) test does NOT exclude infection with dimorphic fungi, and you should never rely on BDG alone when dimorphic fungi are in your differential diagnosis.

Why BDG Cannot Be Used to Rule Out Dimorphic Fungi

The most recent guideline evidence (2025) explicitly states that BDG is typically negative in mucormycosis and cryptococcosis 1. However, the relationship between BDG and dimorphic fungi is more complex and variable:

BDG Can Be Positive with Some Dimorphic Fungi

• Coccidioides infection can result in a positive BDG test result 2, meaning BDG has unpredictable sensitivity for this dimorphic fungus
• Histoplasma can cause positive BDG tests - a 2026 case report documented a patient with disseminated histoplasmosis who had positive BDG 3, and research from 2005 showed all six Histoplasma antigen-positive patients were also BDG positive 4
• The 2025 guideline notes that galactomannan (GM) will be positive in some non-Aspergillus infections including Histoplasma 1, and since BDG is a broader marker than GM, cross-reactivity occurs

The Critical Problem: Variable and Unpredictable Sensitivity

The sensitivity of BDG for dimorphic fungi is inconsistent and poorly characterized. A negative result tells you nothing definitive because:

• BDG may be negative even when dimorphic fungal infection is present
• The test was primarily developed and validated for Candida, Aspergillus, and Pneumocystis - not for dimorphic fungi
• Research suggests BDG may be "most useful for excluding invasive fungal infection" 4, but this applies to the fungi it was designed to detect, not dimorphic organisms

What You Should Do Instead

For Suspected Coccidioidomycosis

Use multiple diagnostic modalities simultaneously - never rely on a single test 2:

• Direct visualization and culture of sputum, BAL, or biopsy material (though sensitivity is low)
• Urine and serum antigen testing (particularly important in immunocompromised patients) 2
• Serology (serum antibody testing) using EIA followed by confirmatory ID or CF 2
• The 2019 ATS guideline emphasizes that no single test is adequate; tailor your approach based on illness severity and test availability 2

For Suspected Histoplasmosis

• Urine Histoplasma antigen is highly sensitive for disseminated disease 1
• Serum antigen testing
• Blood film review may show yeast-like cytoplasmic inclusions in neutrophils 3
• Culture and histopathology when feasible

For Other Dimorphic Fungi (Blastomyces, etc.)

• Antigen testing where available
• Serology (though cross-reactivity between Blastomyces and Histoplasma antibody tests can occur) 1
• Culture and histopathology remain critical

Key Clinical Pitfalls

Do not let a negative BDG falsely reassure you. The most dangerous mistake is excluding dimorphic fungi from your differential based on negative BDG alone. Consider these factors:

• Prior antifungal therapy dramatically reduces sensitivity of all fungal tests, including BDG 1
• Timing matters - early in infection, antigen levels may not be high enough to detect 1
• Geographic exposure and clinical context trump any single negative test 2

The Bottom Line for Clinical Practice

When dimorphic fungi are in your differential diagnosis based on geographic exposure, immune status, and clinical presentation, proceed with organism-specific testing (antigen, serology, culture) regardless of BDG results. The negative predictive value of BDG for dimorphic fungi is unknown and cannot be relied upon to exclude these life-threatening infections.